Basement membrane protein ladinin-1 and the MIF-CD44-β1 integrin signaling axis are implicated in laryngeal cancer metastasis

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1862, Issue 10, 2016, Pages 1938-1954

  Klobučar, Marko ^a   Sedić, Mirela ^a   Gehrig, Peter ^b   Grossmann, Jonas ^b   Bilić, Mario ^c   Kovač Bilić, Lana ^c   Pavelić, Krešimir ^a   Kraljević Pavelić, Sandra ^a  

^a Centre for High throughput Technologies Radmile Matej i 2   (Croatia)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c University Department of Surgery   (Croatia)

Author keywords

Cytoskeleton; Ladinin 1; Metastases; Proteomics; Squamous larynx cancer; Src tyrosine kinase

Indexed keywords

ACTIN BINDING PROTEIN; BETA1 INTEGRIN; CORONIN 1C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LADININ 1; MEMBRANE PROTEIN; PLASTIN 2; PROTEIN CD44; PROTEIN MIF; PROTEIN TYROSINE KINASE; SRC TYROSINE KINASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL INVASION; CELL MOTILITY; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; LARYNX CANCER; MALE; METASTASIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84980357062     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2016.07.014     Document Type: Article

References (46)

1. [1] Wiest, I., Alexiou, C., Mayr, D., Schulze, S., Kuhn, C., Kunze, S., Buttner, M., Betz, P., Jeschke, U., Expression of the carbohydrate tumor marker Sialyl Lewis a (Ca19-9) in squamous cell carcinoma of the larynx. Anticancer Res 30:5 (2010), 1849–1853.
2. [2] Lothaire, P., de Azambuja, E., Dequanter, D., Lalami, Y., Sotiriou, C., Andry, G., Castro, G. Jr., Awada, A., Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck 28:3 (2006), 256–269.
3. [3] Cortesina, G., Martone, T., Molecular metastases markers in head and neck squamous cell carcinoma: review of the literature. Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale, Vol. 26(6), 2006, 317–325.
4. [4] Smith, B.D., Haffty, B.G., Sasaki, C.T., Molecular markers in head and neck squamous cell carcinoma: their biological function and prognostic significance. Ann. Otol. Rhinol. Laryngol 110:3 (2001), 221–228.
5. [5] Hardisson, D., Molecular pathogenesis of head and neck squamous cell carcinoma. Eur. Arch. Otorhinolaryngol 260:9 (2003), 502–508.
6. [6] Feng, Z., Xie, Q., Chen, W.T., Epigenetic and genetic alterations-based molecular classification of head and neck cancer. Expert. Rev. Mol. Diagn 12:3 (2012), 279–290.
7. [7] Zha, C., Jiang, X.H., Peng, S.F., iTRAQ-based quantitative proteomic analysis on S100 calcium binding protein A2 in metastasis of laryngeal cancer. PLoS One, 2015, 10(4).
8. [8] Zhou, J., Fu, Z., Li, J., Wei, L., Li, J., Identification of tumor-associated proteins in well differentiated laryngeal squamous cell carcinoma by proteomics. Clin. Proteomics 3:1 (2007), 42–47.
9. [9] Li, L., Zhang, Z.W., Wang, C.Y., Miao, L., Zhang, J.P., Wang, J.S., Jiao, B.H., Zhao, S.W., Quantitative proteomics approach to screening of potential diagnostic and therapeutic targets for laryngeal carcinoma. PLoS One, 2014, 9(2).
10. [10] Zhang, Y., Zhang, Z.X., Yang, L., Xu, B., Li, W.H., Tang, P.Z., Zhang, Z.M., Han, N.J., Gao, Y.N., Cheng, S.J., et al. Identification of human tissue kallikrein 6 as a potential marker of laryngeal cancer based on the relevant secretory/releasing protein database. Dis. Markers, 2014.
11. [11] Pavelic, S.K., Klobucar, M., Sedic, M., Micek, V., Gehrig, P., Grossman, J., Pavelic, K., Vojnikovic, B., UV-induced retinal proteome changes in the rat model of age-related macular degeneration. Biochim. Biophys. Acta (BBA) - Mol. Basis Dis 1852:9 (2015), 1833–1845.
12. [12] Sedic, M., Poznic, M., Gehrig, P., Scott, M., Schlapbach, R., Hranjec, M., Karminski-Zamola, G., Pavelic, K., Pavelic, S.K., Differential antiproliferative mechanisms of novel derivative of benzimidazo[1,2-alpha]quinoline in colon cancer cells depending on their p53 status. Mol. Cancer Ther 7:7 (2008), 2121–2132.
13. [13] Greene, F.L., Page, D.L., Fleming, I.D., Fritz, A., Balch, C.M., Haller, D.G., Morrow, M., AJCC Cancer Staging Manual (6th Edition). 2002, Springer, 17–89 Part II.
14. [14] Kall, L., Storey, J.D., MacCoss, M.J., Noble, W.S., Assigning significance to peptides identified by tandem mass spectrometry using decoy databases. J. Proteome Res 7:1 (2008), 29–34.
15. [15] Aldridge, G.M., Podrebarac, D.M., Greenough, W.T., Weiler, I.J., The use of total protein stains as loading controls: an alternative to high-abundance single-protein controls in semi-quantitative immunoblotting. J. Neurosci. Methods 172:2 (2008), 250–254.
16. [16] Antonelli, A.R., Nicolai, P., Cappiello, J., Peretti, G., Tosatti, M.P.M., Rosa, D., Grigolato, P.G., Favret, M., Maroccolo, D., Basement-membrane components in normal, dysplastic, neoplastic laryngeal tissue and metastatic lymph-nodes. Acta Otolaryngol 111:2 (1991), 437–443.
17. [17] Hagedorn, H., Schreiner, M., Wiest, I., Tubel, J., Schleicher, E.D., Nerlich, A.G., Defective basement membrane in laryngeal carcinomas with heterogeneous loss of distinct components. Hum. Pathol 29:5 (1998), 447–454.
18. [18] Visser, R., Vanderbeek, J.M.H., Havenith, M.G., Cleutjens, J.P.M., Bosman, F.T., Immunocytochemical detection of basement-membrane antigens in the histopathological evaluation of laryngeal dysplasia and neoplasia. Histopathology 10:2 (1986), 171–180.
19. [19] Rosenthal, E.L., Shreenivas, S., Peters, G.E., Grizzle, W.E., Desmond, R., Gladson, C.L., Expression of extracellular matrix metalloprotease inducer in laryngeal squamous cell carcinoma. Laryngoscope 113:8 (2003), 1406–1410.
20. [20] Motoki, K., Megahed, M., LaForgia, S., Uitto, J., Cloning and chromosomal mapping of mouse ladinin, a novel basement membrane zone component. Genomics 39:3 (1997), 323–330.
21. [21] Larue, L., Bellacosa, A., Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3 ‘ kinase/AKT pathways. Oncogene 24:50 (2005), 7443–7454.
22. [22] Rodrigo, J.P., Dominguez, F., Alvarez, C., Marinque, C., Herrero, A., Suarez, C., Expression of E-cadherin in squamous cell carcinomas of the supraglottic larynx with correlations to clinicopathological features. Eur. J. Cancer 38:8 (2002), 1059–1064.
23. [23] Li, J.J., Zhang, G.H., Yang, X.M., Li, S.S., Liu, X., Yang, Q.T., Li, Y., Ye, J., Reduced E-cadherin expression is associated with lymph node metastases in laryngeal squamous cell carcinoma. Auris Nasus Larynx 39:2 (2012), 186–192.
24. [24] vander Velden, L.A., Schaafsma, H.E., Manni, J.J., Ruiter, D.J., Ramaekers, F.C.S., Kuijpers, W., Cytokeratin and vimentin expression in normal epithelium and squamous cell carcinomas of the larynx. Eur. Arch. Otorhinolaryngol 254:8 (1997), 376–383.
25. [25] Galera-Ruiz, H., Rios-Moreno, M.J., Gonzalez-Campora, R., Ortega, I., Fernandez, A., Garcia-Escudero, A., Galera-Davidson, H., The cadherin-catenin complex in laryngeal squamous cell carcinoma. Eur. Arch. Otorhinolaryngol 269:4 (2012), 1183–1188.
26. [26] Gimond, C., van Der Flier, A., van Delft, S., Brakebusch, C., Kuikman, I., Collard, J.G., Fässler, R., Sonnenberg, A., Induction of cell scattering by expression of beta1 integrins in beta1-deficient epithelial cells requires activation of members of the rho family of GTPases and downregulation of cadherin and catenin function. J. Cell Biol 147:6 (1999), 1325–1340.
27. [27] McFarlane, S., McFarlane, C., Montgomery, N., Hill, A., Waugh, D.J., CD44-mediated activation of alpha5beta1-integrin, cortactin and paxillin signaling underpins adhesion of basal-like breast cancer cells to endothelium and fibronectin-enriched matrices. Oncotarget 6:34 (2015), 36762–36773.
28. [28] Esteban, F., Bravo, J.J., Gonzalez-Moles, M.A., Bravo, M., Ruiz-Avila, I., Gil-Motoya, J.A., Adhesion molecule CD44 as a prognostic factor in laryngeal cancer. Anticancer Res 25:2A (2005), 1115–1121.
29. [29] Ioachim, E., Assimakopoulos, D., Goussia, A.C., Peschos, D., Skevas, A., Agnantis, N.J., Glycoprotein CD44 expression in benign, premalignant and malignant epithelial lesions of the larynx: an immunohistochemical study including correlation with Rb, p53, Ki-67 and PCNA. Histol. Histopathol 14:4 (1999), 1113–1118.
30. [30] Hirvikoski, P., Tammi, R., Kumpulainen, E., Virtaniemi, J., Parkkinen, J.J., Tammi, M., Johansson, R., Agren, U., Karhunen, J., Kosma, V.M., Irregular expression of hyaluronan and its CD44 receptor is associated with metastatic phenotype in laryngeal squamous cell carcinoma. Virchows Arch 434:1 (1999), 37–44.
31. [31] Shi, X.R., Leng, L., Wang, T., Wang, W.K., Du, X., Li, J., McDonald, C., Chen, Z., Murphy, J.W., Lolis, E., et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 25:4 (2006), 595–606.
32. [32] Taher, T.E.I., Smit, L., Griffioen, A.W., SchilderTol, E.J.M., Borst, J., Pals, S.T., Signaling through CD44 is mediated by tyrosine kinases - association with p56(lck) in T lymphocytes. J. Biol. Chem 271:5 (1996), 2863–2867.
33. [33] Kindt, N., Preillon, J., Kaltner, H., Gabius, H.J., Chevalier, D., Rodriguez, A., Johnson, B.D., Megalizzi, V., Decaestecker, C., Laurent, G., et al. Macrophage migration inhibitory factor in head and neck squamous cell carcinoma: clinical and experimental studies. J. Cancer Res. Clin. Oncol. 139:5 (2013), 727–737.
34. [34] Kindt, N., Lechien, J.R., Nonclercq, D., Laurent, G., Saussez, S., Involvement of CD74 in head and neck squamous cell carcinomas. J. Cancer Res. Clin 140:6 (2014), 937–947.
35. [35] Kindt, N., Laurent, G., Nonclercq, D., Journe, F., Ghanem, G., Duvillier, H., Gabius, H.J., Lechien, J., Saussez, S., Pharmacological inhibition of macrophage migration inhibitory factor interferes with the proliferation and invasiveness of squamous carcinoma cells. Int. J. Oncol. 43:1 (2013), 185–193.
36. [36] Meyer-Siegler, K.L., Iczkowski, K.A., Leng, L., Bucala, R., Vera, P.L., Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J. Immunol 177:12 (2006), 8730–8739.
37. [37] Lee, C.Y., Su, M.J., Huang, C.Y., Chen, M.Y., Hsu, H.C., Lin, C.Y., Tang, C.H., Macrophage migration inhibitory factor increases cell motility and up-regulates alphavbeta3 integrin in human chondrosarcoma cells. J. Cell. Biochem 113:5 (2012), 1590–1598.
38. [38] Hoesel, B., Schmid, J.A., The complexity of NF-kappaB signaling in inflammation and cancer. Mol. Cancer, 12, 2013, 86.
39. [39] Lin, Y., Bai, L., Chen, W., Xu, S., The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin. Ther. Targets 14:1 (2010), 45–55.
40. [40] Gupta, A., Cao, W., Chellaiah, M.A., Integrin alphavbeta3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-kappaB ligand signaling axis. Mol. Cancer, 11, 2012, 66.
41. [41] Nam, J.M., Ahmed, K.M., Costes, S., Zhang, H., Onodera, Y., Olshen, A.B., Hatanaka, K.C., Kinoshita, R., Ishikawa, M., Sabe, H., Shirato, H., Park, C.C., β1-Integrin via NF-κB signaling is essential for acquisition of invasiveness in a model of radiation treated in situ breast cancer. Breast Cancer Res, 15(4), 2013, R6042.
42. [42] Boggs, A.E., Vitolo, M.I., Whipple, R.A., Charpentier, M.S., Goloubeva, O.G., Ioffe, O.B., Tuttle, K.C., Slovic, J., Lu, Y., Mills, G.B., Martin, S.S., α-Tubulin acetylation elevated in metastatic and basal-like breast cancer cells promotes microtentacle formation, adhesion, and invasive migration. Cancer Res 75:1 (2015), 203–215.
43. [43] Dieplinger, H., Ankerst, D.P., Burges, A., Lenhard, M., Lingenhel, A., Fineder, L., Buchner, H., Stieber, P., Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, Vol. 18(4), 2009, 1127–1133.
44. [44] Melmer, A., Fineder, L., Lamina, C., Kollerits, B., Dieplinger, B., Braicu, I., Sehouli, J., Cadron, I., Vergote, I., Mahner, S., et al. Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer-a study by the OVCAD consortium. Gynecol. Oncol. 128:1 (2013), 38–43.
45. [45] Jackson, D., Craven, R.A., Hutson, R.C., Graze, I., Lueth, P., Tonge, R.P., Hartley, J.L., Nickson, J., Rayner, S.J., Johnston, C., et al. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin. Cancer Res 13:24 (2007), 7370–7379.
46. [46] Aktas, B., Kasimir-Bauer, S., Wimberger, P., Kimmig, R., Heubner, M., Utility of Mesothelin, L1CAM and Afamin as biomarkers in primary ovarian cancer. Anticancer Res 33:1 (2013), 329–336.